Interstitial Lung Disease Clinical Trials in Charleston, South Carolina
5 studies are recruiting for interstitial lung disease in Charleston, South Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their caregivers. The intervention includes a 9-week digital application gui…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Medical University of South Carolina, Charleston, South Carolina
- Run by
- Medical University of South Carolina
-
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Medical University of South Carolina, Charleston, South Carolina
- Locations
- 71 in total
- Run by
- United Therapeutics
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Medical University of South Carolina-Nexus, Charleston, South Carolina
- Locations
- 165 in total
- Run by
- United Therapeutics
-
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
- Stage
- Not phased
- Ages
- 18 to 80
- Site
- Medical University of South Carolina, Charleston, South Carolina
- Locations
- 23 in total
- Run by
- Liquidia Technologies, Inc.
-
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improv…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- aTyr Investigative Site, Charleston, South Carolina
- Locations
- 15 in total
- Run by
- aTyr Pharma, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.